|
|
|
|
|
|
|
09.02.26 - 09:27
|
Gilead Sciences Aktie vor Q4 2025 Zahlen: 156 oder 103 USD? Analysten-Kursziele und Ratings (Aktiencheck)
|
|
|
Foster City (www.aktiencheck.de) - Welche Kursziele und Ratings trauen die Analysten der führenden Banken und Research-Häuser der Aktie des biopharmazeutischen Unternehmens Gilead Sciences Inc. (ISIN: US3755581036, WKN: 885823, Ticker-Symbol: GIS, NASDAQ-Symbol: GILD) vor Bekanntgabe der Q4 2025 Zahlen zu? 156,00 oder 103,00 USD? Wir haben Ihnen die aktuellen Kursziele und Ratings zur Gilead Sciences-Aktie auf einen Blick zusammengestellt. [mehr]...
|
|
|
|
|
|
|
|
|
06.02.26 - 15:12
|
Kite: FDA Approves Label Update For Yescarta (AFX)
|
|
|
FOSTER CITY (dpa-AFX) - Kite, a Gilead Company (GILD), announced the FDA approved an update to the Yescarta prescribing information removing the previous Limitations of Use in patients with relaps......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
27.01.26 - 22:09
|
Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026 (Business Wire)
|
|
|
FOSTER CITY, Calif.--(BUSINESS WIRE)--#Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2025 financial results and guidance will be released on Tuesday, February 10, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's fourth quarter and full year 2025 financial results and provide a business update.
A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, C...
|
|
|
|
|
23.01.26 - 14:57
|
Cell and Gene Therapy Investment Trends Strategic Intelligence Report 2025: Market to Reach $63 Billion by 2031 - ResearchAndMarkets.com (Business Wire)
|
|
|
DUBLIN--(BUSINESS WIRE)--The "Strategic Intelligence: Cell and Gene Therapy Investment Trends" report has been added to ResearchAndMarkets.com's offering.
The market size of CGT products is expected to continue to rise by 2031 and reach $63 billion.
CGTs have yielded commercial gains for several pharma companies. For example, some of the top-selling CGT products include Gilead Sciences' Yescarta (axicabtagene ciloleucel) and Novartis's Zolgensma (onasemnogene abeparvovec) which reported sales of $1.5 billion and $1.2 billion in 2024, respectively. Additionally, Johnson and Johnson's Carvykti earned $963 million while Sarepta's Elevidys earned $820 million in 2024.
Innovative cell and gene therapies (CGTs) have significantly disrupted the treatment landscape for several genetic diseases.
CGT development is still focused on oncology, hematological/blood disorders (such as sickle cell disease, hemophilia, and beta-thalassemia), and neurology. The majority of pipeline cell therapies are autologous therap...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
